



<https://doi.org/10.1038/s41467-020-15721-y>

OPEN

Retraction Note: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer

D. M. Janzen, E. Tiourin, J. A. Salehi, D. Y. Paik, J. Lu, M. Pellegrini & S. Memarzadeh

Retraction of: *Nature Communications* <https://doi.org/10.1038/ncomms8956>, published online 3 August 2015

An investigation of archival materials initiated by the corresponding author of this paper revealed several errors that undermine the central conclusions with regards to the sensitivity of ovarian cancer tumours to the co-therapy of birinapant and carboplatin in vivo. STR profiling evaluation of archival material pertaining to several key experiments revealed that Ovar-3 cells were used in xenografts rather than as stated, S1-GODL cells in Figs. 6b, c, 7 and Supplementary Fig. 8, patient sample II cells in Fig. 8, and MCF7 cells in Supplementary Fig. 9. Given these issues, we wish to retract the Article in its entirety. We deeply regret this circumstance and apologize to the community.

Published online: 30 April 2020



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020